Blood Screening Market worth $8.82 billion by 2030, growing at a CAGR of 8.67% - Exclusive Report by 360iResearch

The Global Blood Screening Market to grow from USD 4.53 billion in 2022 to USD 8.82 billion by 2030, at a CAGR of 8.67%.



Blood Screening Market - Exclusive Report by 360iResearch

PUNE, MAHARASHTRA, INDIA, November 16, 2023 / EINPresswire.com/ -- The "Blood Screening Market by Product & Service (Instruments, Outright Purchase, Reagents & Kits), Technology (ELISA, NAT, NGS), End-User - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Blood Screening Market to grow from USD 4.53 billion in 2022 to USD 8.82 billion by 2030, at a CAGR of 8.67%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/blood-screening?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Blood screening is a crucial aspect of healthcare that involves analyzing and testing blood samples to detect potential health issues, infections, or disorders. It serves as a vital diagnostic and monitoring tool, ensuring the safety of blood transfusions organ transplants, and tracking the prevalence of various diseases in a population. The increasing number of blood donations/transfusions worldwide, the rising prevalence of infectious disorders, and technological advancements in molecular diagnostics increase the need for blood screening. However, high upfront costs associated with implementing new technologies and a lack of awareness about available tools in underdeveloped regions significantly impede the adoption of blood screening. Additionally, manufacturers focusing on next-generation sequencing (NGS), CRISPR gene-editing techniques, and artificial intelligence (AI) diagnostics applications offer promising avenues for improving testing accuracy, speed, and cost-efficiency. Manufacturers

identify novel biomarkers for various diseases and enhance early detection capabilities, leading to better patient outcomes and increased demand for advanced blood screening tests.

Technology: Development of enzyme-linked immunosorbent assay and mass spectrometry technology
Nucleic acid testing (NAT) is a sensitive molecular technique for detecting viral nucleic acids at very low levels in blood samples. Enzyme-linked immunosorbent assay (ELISA) is an immunoassay technique utilized to screen blood samples for antibodies and antigens related to infectious diseases such as HIV, Hepatitis B and C, and Syphilis. Polymerase chain reaction (PCR) is another widely-used molecular diagnostic method that enables rapid detection of specific nucleic acid sequences within a given sample. Mass spectrometry (MS) is an analytical process for identifying and characterizing molecules based on their mass-to-charge ratio (m/z). Flow cytometry is a cell-based technology that allows for rapid analysis of cellular properties by measuring the scattering of light as cells flow through a laser beam.

End-User: Increasing use of blood screening in hospitals and laboratories
Hospitals & clinics serve as primary contact points for patients needing blood tests as part of their medical treatment or diagnosis. They collect and process samples on-site or send them to external laboratories for further analysis. Diagnostic laboratories specialize in analyzing biological samples through an array of testing methods such as nucleic acid amplification tests (NAAT), enzyme-linked immunosorbent assay (ELISA), or chemiluminescent immunoassay (CIA). For transfusion, blood banks collect, store, process, test, and distribute blood products, such as whole blood, plasma, platelets, red cells, and white cells. Research institutions, including universities, government agencies, and private organizations, contribute to the development of novel technologies and methodologies for blood screening.

Application: Significant applications of infectious disease and cancer screening to prevent the spread of infections
Blood screening for infectious diseases is critical for supporting public health and preventing the spread of infections. Blood typing is an essential blood screening process to determine an individual's blood group (ABO system) and Rh factor (positive or negative). Early detection through cancer-specific blood screening has become increasingly relevant with advancements in diagnostic technology. Genetic blood tests analyze DNA to identify inherited disorders, assess the risk of developing specific diseases, and guide personalized treatment plans.

Product: Rising adoption of instruments and consumables for conducting accurate tests
The blood screening process relies heavily on sophisticated instruments capable of conducting rapid and accurate tests for various pathogens. These instruments help detect infectious agents and enable healthcare professionals to quantify their presence in a given sample. Consumables facilitate accurate and efficient testing while minimizing risks associated with cross-contamination between samples. Consumables in blood screening include micropipette tips, microplates, filter tips & tubes, cuvettes & vials, syringe filters, and other disposable equipment. Blood screening also heavily depends on various reagents that react with specific pathogens or

compounds within a sample to produce measurable signals indicating the presence of infectious agents.

Regional Insights:
In the Americas, the demand for blood screening tests is increasing due to their advanced healthcare systems, high-quality research institutions, and funding for innovation. The U.S. Food and Drug Administration (FDA) significantly approves new blood screening technologies to ensure safety and efficacy. In Asia Pacific, rapid economic growth, expanding healthcare infrastructure, and a large patient population are prone to infectious diseases due to high population density. China has recently implemented stringent blood safety regulations following past transfusion-related scandals, leading to increased demand for advanced screening technologies. The European Union (EU) countries have a highly developed healthcare system with strict blood transfusion services regulations. Investments in R&D activities focused on novel diagnostic technologies contribute to Europe's robust blood screening industry. The Middle East & Africa region showcases a diverse landscape with varying levels of healthcare infrastructure development. Many African countries face challenges relating to inadequate infrastructure and resources for ensuring safe transfusions, posing health risks to recipients.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Blood Screening Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Blood Screening Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Blood Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alfa Scientific Designs, Inc., Becton, Dickinson And Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, bioMérieux SA, Danaher Corporation, DiaSorin S.p.A., Environmental & Scientific Instruments Co., F. Hoffmann-La Roche AG, GE HealthCare Technologies, Inc., GFE, Grifols, S.A., Immucor, Inc., Laboratory Corporation of America Holdings, Lifeloc Technologies,

Inc, Omega Laboratories, Inc., OraSure Technologies, Inc., Ortho Clinical Diagnostics, Inc., PerkinElmer, Inc., PixCell Medical Technologies Ltd., Premier Biotech, Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Trinity Biotech Plc.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/blood-screening?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Blood Screening Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product & Service, market is studied across Instruments, Outright Purchase, and Reagents & Kits. The Reagents & Kits is further studied across ELISA Reagents & Kits and NAT Reagents & Kits. The ELISA Reagents & Kits is further studied across Conjugates, Controls, Immunosorbents, Sample Diluents & Wash Solutions, and Substrates. The NAT Reagents & Kits is further studied across Buffers, Nucleotides, & Solutions, Enzymes & Polymerases, Labeling & Detection Reagents, Probes & Primers, and Standards & Controls. The Reagents & Kits is projected to witness significant market share during forecast period.

Based on Technology, market is studied across ELISA, NAT, NGS, Rapid Tests, and Western Blot Assays. The ELISA is further studied across Chemiluminescent Immunoassay, Colorimetric Immunoassay, and Fluorescent immunoassay. The NAT is further studied across Real-Time Polymerase Chain Reaction and Transcription-Mediated Amplification. The Rapid Tests is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Blood Banks and Hospitals. The Blood Banks is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

1. Preface

2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Blood Screening Market, by Product & Service
7. Blood Screening Market, by Technology
8. Blood Screening Market, by End-User
9. Americas Blood Screening Market
10. Asia-Pacific Blood Screening Market
11. Europe, Middle East & Africa Blood Screening Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Blood Screening Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Blood Screening Market?
3. What is the competitive strategic window for opportunities in the Blood Screening Market?
4. What are the technology trends and regulatory frameworks in the Blood Screening Market?
5. What is the market share of the leading vendors in the Blood Screening Market?
6. What modes and strategic moves are considered suitable for entering the Blood Screening Market?

Read More @ https://www.360iresearch.com/library/intelligence/blood-screening?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+ 1 530-264-8485

ketan@360iresearch.com